Shares of Verastem Inc (NASDAQ:VSTM) have been assigned a consensus rating of “Buy” from the ten analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $10.36.
VSTM has been the topic of several recent research reports. Cann reiterated a “buy” rating and issued a $13.00 price objective on shares of Verastem in a research report on Friday, January 26th. Oppenheimer set a $13.00 price objective on shares of Verastem and gave the stock a “buy” rating in a research report on Thursday, December 21st. HC Wainwright set a $10.00 price objective on shares of Verastem and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Raymond James Financial reiterated a “buy” rating on shares of Verastem in a research report on Monday, December 11th. Finally, Cantor Fitzgerald set a $17.00 target price on shares of Verastem and gave the company a “buy” rating in a research note on Sunday, December 10th.
In other news, Director Timothy J. Barberich bought 60,538 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The stock was purchased at an average price of $3.95 per share, with a total value of $239,125.10. Following the purchase, the director now owns 130,000 shares of the company’s stock, valued at approximately $513,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.51% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new position in shares of Verastem during the 3rd quarter valued at about $136,000. SeaCrest Wealth Management LLC acquired a new position in shares of Verastem during the 4th quarter valued at about $108,000. Spark Investment Management LLC acquired a new position in shares of Verastem during the 4th quarter valued at about $113,000. Citadel Advisors LLC acquired a new position in shares of Verastem during the 3rd quarter valued at about $195,000. Finally, Wells Fargo & Company MN increased its stake in shares of Verastem by 130.5% during the 4th quarter. Wells Fargo & Company MN now owns 45,987 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 26,036 shares during the last quarter. 29.10% of the stock is owned by hedge funds and other institutional investors.
Verastem (NASDAQ:VSTM) traded down $0.08 during trading on Friday, hitting $3.22. 328,913 shares of the company traded hands, compared to its average volume of 764,188. Verastem has a 1-year low of $1.11 and a 1-year high of $5.71. The company has a quick ratio of 3.12, a current ratio of 3.12 and a debt-to-equity ratio of 0.06. The stock has a market cap of $139.43, a price-to-earnings ratio of -1.98 and a beta of 2.20.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/22/verastem-inc-vstm-given-average-recommendation-of-buy-by-analysts.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.